Extracorporeal shock wave therapy for treating dyspareunia: A prospective, randomized, double-blind, placebo-controlled study

Background: Dyspareunia is a genital pain during or after penile-vaginal sexual intercourse. It is a painful spasm of the pelvic muscles that partly or entirely disables vaginal penetration. Objectives: We examined the effect of extracorporeal shock wave therapy (ESWT) on idiopathic non organic dyspareunia in women. A prospective, randomized, double-blind, placebo-controlled study was conducted. Methods: The study included 62 women who reported dyspareunia. Patients in the treatment and placebo groups received ESWT perineally weekly for 4 consecutive weeks; placebo patients received placebo stand-off treatment. The grade of dyspareunia was estimated by using the Marinoff Dyspareunia Scale and subjective pain intensity on a visual analog scale (VAS) before and after treatment. Follow-ups were conducted 1, 4 and 12 weeks after the final ESWT session. Results: The study included 61 women. The treatment but not placebo group differed by the Marinoff Dyspareunia Scale and VAS. Differences before and after treatment within groups were all P < 0.001 and between groups, P < 0.001. Pain reduction was always > 30%. The effect sizes were both large: Marinoff 0.825 and VAS 0.883. Conclusions: ESWT significantly reduced subjective pain in our women treated for dyspareunia. (C) 2021 The Author(s). Published by Elsevier Masson SAS.

Automated summary

The study investigated the effect of extracorporeal shock wave therapy (ESWT) on idiopathic non organic dyspareunia in women. Results showed that ESWT significantly reduced subjective pain in the treated women, with pain reduction consistently exceeding 30% and large effect sizes for both Marinoff Dyspareunia Scale and VAS.